MELLIsim aims to develop and commercialise a new and revolutionary continuous glucose biosensor. The first solution addresses the unmet needs of Type 2 Diabetic (T2D) patients.

​

Since 2015, the team has been working closely with a leading research laboratories in biosensors, to develop an innovative sensing solution.

​

In 2019, after four years of technology maturation with the support of patient associations and renowned hospital specialists in France, Switzerland, England and Canada, MELLIsim was created with the purpose of delivering this new effective solution.

​

The MELLIsim team is highly motivated to bring to the market MELLIsense, a disruptive solution that is expected by patients and healthcare professionals.

 

First MELLIsense aims to significantly change and correct the current status of poorly controlled Type 2 Diabetic patients. It is one of the most ground-breaking changes in the last 20 years for these patients with huge medical and societal impacts. MELLIsim aims to become a champion in diabetes care.

​

Our goal is to have our solution largely deployed among the 7.6 million first targeted patients in Europe, the US and Canada. To achieve this, we are setting up partnerships to distribute our solution worldwide.